{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:10:20Z","timestamp":1791897020899,"version":"4.3.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Behav. Neurosci."],"abstract":"<jats:p>Huntington's disease (HD) is a progressive, fatal neurodegenerative disorder with limited treatment options. Substantial evidence implicates mitochondria dysfunction in brain and skeletal muscle in the pathogenesis of HD. Metabolic strategies, such as fasting and ketogenic diets, theoretically enhance brain and muscle metabolism and mitochondria function, which may improve the clinical symptoms of HD. We report the case of a 41-year-old man with progressive, deteriorating HD who pursued a time-restricted ketogenic diet (TRKD) for 48 weeks. Improvements were measured in his motor symptoms (52% improvement from baseline), activities of daily living (28% improvement), composite Unified HD Rating Scale (cUHDRS) score (20% improvement), HD-related behavior problems (apathy, disorientation, anger, and irritability improved by 50\u2013100%), and mood-related quality of life (25% improvement). Cognition did not improve. Weight remained stable and there were no significant adverse effects. This case study is unique in that a patient with progressive, deteriorating HD was managed with a TRKD, with subsequent improvements in his motor symptoms, activities of daily living, cUHDRS score, most major HD-related behavior problems, and quality of life. Our patient remains dedicated to his TRKD, which continues to provide benefit for him and his family.<\/jats:p>","DOI":"10.3389\/fnbeh.2022.931636","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T09:06:50Z","timestamp":1659085610000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Time-Restricted Ketogenic Diet in Huntington's Disease: A Case Study"],"prefix":"10.3389","volume":"16","author":[{"given":"Matthew C. L.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen J.","family":"McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Brinkhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Romero-Ferrando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","article-title":"Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease","volume":"119","author":"Antonini","year":"1996","journal-title":"Brain."},{"key":"B2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fnins.2020.00082","article-title":"Cortical and striatal circuits in Huntington's disease","volume":"14","author":"Blumenstock","year":"2020","journal-title":"Front. Neurosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ana.410410514","article-title":"Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia","volume":"41","author":"Browne","year":"1997","journal-title":"Ann. Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mds.870080212","article-title":"Assessment of adaptive functioning in Huntington's disease","volume":"8","author":"Bylsma","year":"1993","journal-title":"Mov. Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.yebeh.2016.02.038","article-title":"Establishing an adult epilepsy diet center: experience, efficacy and challenges","volume":"58","author":"Cervenka","year":"2016","journal-title":"Epilepsy Behav."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1093\/hmg\/ddp243","article-title":"Impaired PGC-1\u03b1 function in muscle in Huntington's disease","volume":"18","author":"Chaturvedi","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/mds.23258","article-title":"Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington's disease","volume":"26","author":"Ciammola","year":"2011","journal-title":"Mov. Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current pharmacological approaches to reduce chorea in Huntington's disease","volume":"77","author":"Coppen","year":"2017","journal-title":"Drugs."},{"key":"B9","unstructured":"Behavioral changes in Huntington disease219226\n            CraufurdD.\n            ThompsonJ. C.\n            SnowdenJ. S.\n          Neuropsychiatry Neuropsychol. Behav. Neurol.142001"},{"key":"B10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","article-title":"Transcriptional repression of PGC-1\u03b1 by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration","volume":"127","author":"Cui","year":"2006","journal-title":"Cell."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1056\/NEJMra1905136","article-title":"Effects of intermittent fasting on health, aging, and disease","volume":"381","author":"de Cabo","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jchemneu.2004.02.005","article-title":"Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study","volume":"27","author":"Deng","year":"2004","journal-title":"J. Chem. Neuroanat."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1073\/pnas.0536856100","article-title":"Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice","volume":"100","author":"Duan","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/archneur.1992.00530350075022","article-title":"Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease","volume":"49","author":"Grafton","year":"1992","journal-title":"Arch. Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ana.410390317","article-title":"Mitochondrial defect in Huntington's disease caudate nucleus","volume":"39","author":"Gu","year":"1996","journal-title":"Ann. Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/mds.22412","article-title":"Health-related quality of life in Huntington's disease: which factors matter most?","volume":"24","author":"Ho","year":"2009","journal-title":"Mov. Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jval.2019.01.016","article-title":"Meaningful and measurable health domains in Huntington's disease: large-scale validation of the Huntington's disease health-related quality of life questionnaire across severity stages","volume":"22","author":"Ho","year":"2019","journal-title":"Value Health."},{"key":"B18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's disease rating scale: reliability and consistency","volume":"11","year":"1996","journal-title":"Mov. Disord."},{"key":"B19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","year":"2006","journal-title":"Neurology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1093\/hmg\/ddq306","article-title":"Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease","volume":"19","author":"Kim","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s43587-020-00013-3","article-title":"Intermittent and periodic fasting, longevity and disease","volume":"1","author":"Longo","year":"2021","journal-title":"Nat. Aging."},{"key":"B22","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1126\/science.aau2096","article-title":"Dietary fat: from foe to friend?","volume":"362","author":"Ludwig","year":"2018","journal-title":"Science."},{"key":"B23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington's disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"5157645","DOI":"10.1155\/2018\/5157645","article-title":"Nutritional ketosis and mitohormesis: potential implications for mitochondrial function and human health","volume":"2018","author":"Miller","year":"2018","journal-title":"J. Nutr. Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1136\/jnnp-2012-304558","article-title":"Beyond and below the cortex: The contribution of striatal dysfunction to cognition and behaviour in neurodegeneration","volume":"85","author":"O'Callaghan","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1471-4159.2010.06741.x","article-title":"Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum","volume":"114","author":"Oliveira","year":"2010","journal-title":"J. Neurochem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/MED.0000000000000569","article-title":"Effect of low-carbohydrate diets on cardiometabolic risk, insulin resistance, and metabolic syndrome","volume":"27","author":"O'Neill","year":"2020","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"B28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.14336\/AD.2021.1018","article-title":"Metabolic strategies in healthcare: a new era","volume":"13","author":"Phillips","year":"2022","journal-title":"Aging Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","article-title":"Differential loss of striatal projection neurons in Huntington disease","volume":"85","author":"Reiner","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.physbeh.2011.04.001","article-title":"ketogenic diet delays weight loss and does not impair working memory or motor function in the R6\/2 1J mouse model of Huntington's disease","volume":"103","author":"Ruskin","year":"2011","journal-title":"Physiol. Behav."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1212\/WNL.0000000000004743","article-title":"Motor, cognitive, and functional declines contribute to a single progressive factor in early HD","volume":"89","author":"Schobel","year":"2017","journal-title":"Neurology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1037\/h0054651","article-title":"Studies of interference in serial verbal reactions","author":"Stroop","year":"1935","journal-title":"J. Exp. Psychol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1301\/nr.2003.oct.327-341","article-title":"Ketones: metabolism's ugly duckling","volume":"61","author":"VanItallie","year":"2003","journal-title":"Nutr. Rev"},{"key":"B36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/152165401753311780","article-title":"Ketone bodies, potential therapeutic uses","volume":"51","author":"Veech","year":"2001","journal-title":"IUBMB Life."}],"container-title":["Frontiers in Behavioral Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnbeh.2022.931636\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T09:06:55Z","timestamp":1659085615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnbeh.2022.931636\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":36,"alternative-id":["10.3389\/fnbeh.2022.931636"],"URL":"https:\/\/doi.org\/10.3389\/fnbeh.2022.931636","relation":{},"ISSN":["1662-5153"],"issn-type":[{"value":"1662-5153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"article-number":"931636"}}